Novartis AG said Friday its leukemia drug candidate Tasigna received priority review by the Food and Drug Administration.
The special designation speeds up the regulatory review process to six months from the usual 10 months.
Novartis, based in Switzerland, also makes the cancer drug Gleevec.
© Copyright 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.